Biomarker Core

该核心协调患者登记，组织临床数据，并规范临床标本和生物测定的收集。在这样做的过程中，Core将利用在斯坦福大学随访的肺动脉高压（PAH）、有呼吸机诱导新生儿肺损伤（VIINL）或慢性肺病（CLD）风险的患者和肺移植（LT）候选者的大队列。他们将开展一个已建立的最先进的细胞和液体生物测定平台，这些生物测定将与反映疾病严重性的生理终点相关。

This Core coordinates patient enrollment, organizes clinical data, and standardizes collection of clinical specimens and bioassays. In so doing, the Core will leverage the large cohorts of patients with Pulmonary Arterial Hypertension (PAH), at risk for Ventilator Induced Injury of the Newborn Lung (VIINL) or chronic lung disease (CLD) and candidates for Lung Transplantation (LT) followed at the Stanford. They will carry out an established platform of state-of-the-art bioassays for cells and fluids that will be related to physiological endpoints that reflect disease severity.